In this issue:
REMIX-1 & -2 trials: remibrutinib in CSU
Paradoxical urticaria with H1 antihistamines
Urticaria Voices survey: disease burden of CSU
Chronic urticaria after COVID-19 infection
CSU prognosis after omalizumab nonresponse
Real-world omalizumab for CIndU
Gut dysbiosis in refractory CSU
Teledermatology for CSU
WAO position on CSU remission
Ligelizumab in refractory CSU
Please login below to download this issue (PDF)